Genodermatoses are heritable skin diseases that can cause significant morbidity and mortality. Most of them show characteristic cutaneous findings. Genodermatoses can be associated with extracutaneous system abnormalities. Diagnosing hereditary skin disorders is still a challenging task due to their rarity and diversity, due to diseases evolving over many years, and the initial manifestations not always being diagnostic; therefore, ongoing evaluation and surveillance is often required to make the accurate diagnosis. The algorithm for the diagnosis depends on a combination of thorough clinical and family history clinical examination, laboratory findings, consultation of multiple medical specialists, and molecular analysis. Diagnostic testing targeted at differentiation of similar genodermatoses may be required. Recognition is crucial for the initiation of the treatment for skin manifestations and detection of other extracutaneous abnormalities, including malignancy. Diagnostic accuracy and molecular diagnosis may help in providing a template for ongoing management, testing, and education and prognostication for families of children with genodermatoses. Read the whole article here.
The Bulgarian Hemophilia Association organizes an information campaign on the occasion of the World Hemophilia Day – April 17. The campaign will be held under the title “We are moving together with the change!”, and the association calls on everyone who wish to join the dissemination of information materials that will be published through their communication channels.
By bringing together as many people as possible in this year’s hashtag campaign on social media #движимсезаедноспромяната and #световенденахемофилията the association aims first to inform the general public about all the specifics of the disease and the needs of each patient in times of isolation and global pandemic, calling on everyone to be together in this new reality.
More information about the campaign can be found at the following link: https://hemo-bg.org/
On 27 March 2021 was held the 8th annual symposium “HEALTH TECHNOLOGY ASSESSMENT – STRATEGIES FOR ACCELERATED ACCESS, organized by the Institute for Rare Diseases. For the first year, the event took place online in the digital platform Virtual Congress Venue, thus facilitating interactive discussions between participants from different countries such as the UK, Singapore, Slovakia, Romania, Czech republic, etc. Experts from Israel, Spain, France, Poland, Switzerland and Bulgaria shared their global, country-specific, academic and regulatory experience in international reference pricing, negotiation of discounts and rebates and managed entry agreements. The main topics of the discussions were health technology assessment, sustainable access to innovative therapies within limited budgets, as well as decision-making tools.
Information on topics and speakers at: https://vcv.raredis.org/en/event/health-technology-assessment-strategies-for-accelerated-access/
Vitamin D is a fat-soluble steroid hormone playing a pivotal role in calcium and phosphate homeostasis as well as in bone health. Vitamin D levels are not exclusively dependent on food intake. Indeed, the endogenous production-occurring in the skin and dependent on sun exposure-contributes to the majority amount of vitamin D present in the body. Since vitamin D receptors (VDRs) are ubiquitous and drive the expression of hundreds of genes, the interest in vitamin D has tremendously grown and its role in different diseases has been extensively studied. Several investigations indicated that vitamin D action extends far beyond bone health and calcium metabolism, showing broad effects on a variety of critical illnesses, including cancer, infections, cardiovascular and autoimmune diseases. Epidemiological studies indicated that low circulating vitamin D levels inversely correlate with cutaneous manifestations and bone abnormalities, clinical hallmarks of neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant tumour predisposition syndrome causing significant pain and morbidity, for which limited treatment options are available. In this context, vitamin D or its analogues have been used to treat both skin and bone lesions in NF1 patients, alone or combined with other therapeutic agents. Here we provide an overview of vitamin D, its characteristic nutritional properties relevant for health benefits and its role in NF1 disorder. We focus on preclinical and clinical studies that demonstrated the clinical correlation between vitamin D status and NF1 disease, thus providing important insights into disease pathogenesis and new opportunities for targeted therapy. Read the whole article here.
Mastocytosis is a rare disease characterised by expansion and collection of clonal mast cells in various organs including the skin, bone marrow, spleen, lymph nodes and gastrointestinal tract. The prevalence of mastocytosis has been estimated to be one in 10 000, while the estimated incidence is one per 100 000 people per year. Cutaneous mastocytosis is classified into (i) maculopapular cutaneous mastocytosis, also known as urticaria pigmentosa; (ii) diffuse cutaneous mastocytosis; and (iii) mastocytoma of the skin. In adults, cutaneous lesions are usually associated with indolent systemic mastocytosis and have a chronic evolution. Paediatric patients, on the contrary, have often cutaneous manifestations without systemic involvement and usually experience a spontaneous regression. Diagnosis of cutaneous mastocytosis may be challenging due to the rarity of the disease and the overlap of cutaneous manifestations. This short review describes pathogenesis and clinical aspects of cutaneous mastocytosis with a focus on diagnosis and currently available therapies. Read the whole article here.
The 11th National Conference for Rare Diseases and Orphan Drugs, organized by the Institute for Rare Diseases, was held on 11-12 September, 2020. The event was held online for the first year, in a specially developed digital platform – Virtual Congress Venue. The conference presented the new and current trends in the diagnosis, treatment and monitoring of rare diseases, the development of European reference networks and access to innovative technologies. A proceedings book with all presentations and materials presented at the conference are published as a supplement to the scientific journal “Rare Diseases and Orphan Drugs” and can be viewed at the following link.
Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience
Patients with the rare disease hereditary angioedema (HAE) suffer from recurrent acute attacks of edema. There is no curative therapy, but the frequency of attacks and quality of life of severely affected patients can be improved by prophylactic therapy. The monoclonal antibody lanadelumab has been approved for routine prophylaxis in patients with HAE since November 2018. The prospective assessment of this review is initiated by long-term therapy with lanadelumab in 12 adult patients with HAE. It is analyzed their course of disease 6 months after the start of long-term prophylactic therapy using a validated quality-of-life questionnaire and evaluated the frequency and severity of attacks as well as side effects. Furthermore, the therapy with lanadelumab was compared with the previous medication. The result of the research is the first prospective quality of life analysis in HAE patients under treatment with lanadelumab in real life conditions. Mean attack frequencies were reduced from 6.4 to 0.3 attacks per month. No severe attacks occurred under lanadelumab prophylaxis. In all patients, quality of life increased significantly. Read the whole article here.
This year in Plovdiv Rare Disease Day will be celebrated on 28 February, 2021. The initiative will be held under the motto “We are many, we are strong, we are united”. The main focus of the event is pictures with colorful messages, and the different colors are symbol of the thousands types of rare diagnoses in the world. The initiative is organized jointly with the National Alliance of People with Rare Diseases and the HAE Association (hereditary angioedema). Students from the Professional School of Food Technology – Plovdiv, will also take part in the celebration of this important event.
Every year the Rare Disease Day is on the last day of February. The main goal of the campaign is to raise public awareness and the opportunity for timely diagnosis and treatment of those who are affected. The initiative is set up by EURORDIS and the Council of National Alliances for Rare Diseases in 2008 and gradually becoming a global phenomenon. Hundreds of cities take part in this large-scale campaign every year. Due to the pandemic situation, all events will be organized according to the imposed measures.
On 2 March, 2021 at 6:30 pm in hall Varna of the Virtual Congress Venue, psychologist Milena Velinova will present a lecture about “Autism – diagnosis or personal choice”. The webinar is intended for parents and all interested medical professionals, representatives of the academy, health authorities, patient organizations. The lecture concern main topics such as general characteristics and manifestations, diagnostic methods, interaction and approach.
At this link you can register for the event for free.
Acromegaly is a rare disease with a peak of incidence in early adulthood. However, enhanced awareness of this disease, combined with wide availability of magnetic resonance imaging (MRI), has increased the diagnosis of forms with mild presentation, especially in elderly patients. Moreover, due to increased life expectancy and proactive individualized treatment, patients with early-onset acromegaly are today aging. The aim of our study was to describe our cohort of elderly patients with acromegaly.
This is a cross-sectional retrospective study of 96 outpatients. Clinical, endocrine, treatment, and follow-up data were collected using the electronic database of the University Hospital of Padova, Italy.
We diagnosed acromegaly in 13 patients, aged ≥65 years, presenting with relatively small adenomas and low IGF-1 secretion. Among them, 11 patients were initially treated with medical therapy and half normalized hormonal levels after 6 months without undergoing neurosurgery (TNS). Remission was achieved after TNS in three out of four patients (primary TNS in two); ten patients presented controlled acromegaly at the last visit. Acromegaly-related comorbidities (colon polyps, thyroid cancer, adrenal incidentaloma, hypertension, and bone disease) were more prevalent in patients who had an early diagnosis (31 patients, characterized by a longer follow-up of 24 years) than in those diagnosed aged ≥65 years (5 years of follow-up).
Elderly acromegalic patients are not uncommon. Primary medical therapy is a reasonable option and is effectively used, suggesting cost-benefit balance. Disease-specific comorbidities are more prevalent in acromegalic patients with a longer follow-up rather than in those diagnosed aged ≥65 years. Read the whole article here.